Pharmacokinetics of targeting with liposomes

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 19, Issue 3, 2002, Pages 235-275

  Harashima, Hideyoshi ^a   Ishida, Tatsuhiro ^b   Kamiya, Hiroyuki ^a   Kiwada, Hiroshi ^b  

^a HOKKAIDO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Intracellular trafficking; Liposomes; PK PD modeling; Receptor; Targeting

Indexed keywords

ANTIBODY; BETA1 INTEGRIN; CD19 ANTIGEN; COMPLEMENT; DILAUROYLPHOSPHATIDYLCHOLINE; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIOLEOYLPHOSPHATIDYLCHOLINE; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; DISTEAROYLPHOSPHATIDYLCHOLINE; DNA; DOXORUBICIN; EPITOPE; FOLIC ACID; HIGH DENSITY LIPOPROTEIN; HYALURONIC ACID; HYDRAZIDE; IMMUNOLIPOSOME; LIGAND; LIPID; LIPOSOME; MACROGOL DERIVATIVE; MALEIMIDE; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; PHOSPHATIDYLETHANOLAMINE; RECEPTOR; TRANSFERRIN; TUMOR ANTIGEN; UNINDEXED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; ENCAPSULATION; GENE THERAPY; HUMAN; MICHAELIS MENTEN KINETICS; MODEL; NONHUMAN; PH; REVIEW; SURVIVAL; TUMOR GROWTH;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; METABOLIC CLEARANCE RATE;

EID: 0347297454     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v19.i3.20     Document Type: Review

References (173)

1. Harashima H, Kiwada H. Liposomal targeting and drug delivery: kinetic consideration. Adv Drug Deliv Rev 1996; 19:425.
2. Harashima H, Tsuchihashi M, Iida S, Doi H, Kiwada H. Pharmacokinetic/pharmacodynamic modeling of antitumor agents encapsulated into liposomes. Adv Drug Deliv Rev 1999; 40:39.
3. Allen TM, Hansen CB, Stuart DD, Lasic DD, Papahadjopoulos D. Targeted sterically stabilized liposomal drug delivery. In: Lasic DD, editors. Medical applications of liposomes. Amsterdam: Elsevier Science Publications, 1998.
4. Pappenheimer JR, Renkin EM, Borrero LM. Filtration, diffusion and molecular sieving through peripheral capillary membranes. A contribution to the pore theory of capillary permeability. Am J Physiol 1951; 167:13.
5. Rippe B, Haraldsson B. Transport of macromolecules across microvascular walls: The two pore theory. Physiol Rev 1994; 74:163.
6. Gregoriadis G, Senior, J. The phospholipid component of small unilamellar liposomes controls the rate of clearance of entrapped solutes from the circulation. FEBS Lett 1980; 119:43.
7. Senir J, Gregoriadis G. Is half-life of circulating liposomes determined by changes in their permeability? FEBS Lett 1982; 145:109.
8. Allen TM, Austin GA, Chonn A, Lin L, Lee KC. Uptake of liposomes by cultured mouse bone marrow macrophages: influence of liposome composition and size. Biochim Biophys Acta 1991; 1061:56.
9. Senior, J, Gregoriadis G. Stability of small unilamellar liposomes in serum and clearance from the circulation: the effect of the phospholipid and cholesterol components. Life Sci 1982; 30:2123.
10. Patel HM, Tuzel NS, Ryman BE. Inhibitory effect of cholesterol on the uptake of liposomes by liver and spleen. Biochim Biophys Acta 1983; 761:142.
11. Foong WC, Green KL. Association of liposome-entrapped [3H] methotrexate with thioglycollate elicited macrophages in vitro. J Pharm Pharmacol 1988; 40:171.
12. Harashima H, Sakata K, Funato K, Kiwada H. Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes. Pharm Res 1994; 11:402.
13. Funato K, Yoda R, Kiwada H. Contribution of complement system on destabilization of liposomes composed of hydrogenated egg phosphatidylcholine in rat fresh plasma. Biochim Biophys Acta 1992; 1103:198.
14. Souhami R, Patel HM, Ryman BE. The effect of reticuloendothelial blockade on the blood clearance and tissue distribution of liposomes. Biochim Biophys Acta 1981; 674:354.
15. Juliano RL, Stamp D. The effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs. Biochim Biophys Res Comm 1975; 63:651.
16. Beaumier PL, Hwang KJ. Effects of liposome size on the degradation of bovine brain sphingomyelin/cholesterol liposomes in the mouse liver. Biochim Biophys Acta 1983; 731:23.
17. Chow DD, Essien HE, Padki MM, Hwang KJ. Targeting small unilamellar liposomes to hepatic parenchymal cells by dose effect. J Pharm Exp Therap 1989; 248:506.
18. Chonn A, Cullis PR, Devine D. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J Immunol 1991; 146:4234.
19. Cunningham CM, Kingzette M, Richards RL, Alving CR, Lint TF, Gewurz H. Activation of human complement by liposomes: a model for membrane activation of the alternative pathway. J Immunol 1979; 122:1237.
20. Okada N, Yasuda T, Tsumita T, Okada H. Activation of the alternative complement pathway of guinea-pig by liposomes incorporated with trinitrophenylated phosphatidylethanolamine. Immunology 1982; 45:115.
21. Devine D, Wong K, Serrano KA, Chonn A, Cullis PR. Liposome-complement interactions in rat serum: implications for liposome survival studies. Biochim Biophys Acta 1994; 1191:43.
22. Scieszka JF, Maggiora LL, Wright SD, Cho MJ. Role of complements C3 and C5 in the phagocytosis of liposomes by human neutrophils. Pharm Res 1991; 8:65.
23. Brown EJ. Complement receptors and phagocytosis. Curr Opin Immunol 1991; 3:76.
24. Liu Z, Hu VW. Fluorescence analysis of size distribution and mode of dye release from carboxyfluorescein-loaded vesicles: application to the study of complement-membrane interactions. Biochim Biophys Acta 1988; 945:253.
25. Wisse E, De Zanger RB, Charels K, Van Der Smisse P, McCuskey RS. The liver sieve: considerations concerning the structure and function of endothelial fenestrae, the sinusoidal wall and the space of Disse. Hepatology 1985; 5:683.
26. McCuskey RS, McCuskey PA. Fine structure and function of Kupffer cells. J Elec Microsc Tech 1990; 14:237.
27. Rahman YE, Cerny EA, Patel KR, Lau EH, Wright BJ. Differential uptake of liposomes varying in size and lipid composition by parenchymal and Kupffer cells of mouse liver. Life Sci 1982; 31:2061.
28. Harashima H, Huong TM, Ishida T, Manabe Y, Matsuo H, Kiwada H. Synergistic effect between size and cholesterol content in the enhanced hepatic uptake clearance of liposomes through complement activation in rats. Pharm Res 1996; 13:1702.
29. Abra RM, Hunt CA. Liposome disposition in vivo. III. Dose and vesicle-size effects. Biochim Biophys Acta 1981; 666:493.
30. Beaumier PL, Hwang KJ, Slattery JT. Effect of liposome dose on the elimination of small unilamellar sphingomyelin/cholesterol vesicles from circulation. Res Comm Chem Pathol Pharmacol 1983; 39:277.
31. Sato Y, Kiwada H, Kato Y. Effects of dose and vesicle size on the pharmacokinetics of liposomes. Chem Pharm Bull 1986; 34:4244.
32. Harashima H, Yamane C, Kume Y, Kiwada H. Kinetic analysis of AUC-dependent saturable clearance of liposomes: mathematical description of AUC dependency. J Pharmacokin BioPharm 1993; 21:299.
33. Kume Y, Maeda F, Harashima H, Kiwada H. Saturable, non-Michaelis-Menten uptake of liposomes by the reticuloendothelial system. J Pharm Pharmacol 1991; 43:162.
34. Harashima H, Kume Y, Yamane C, Kiwada H. Non-Michaelis-Menten type hepatic uptake of liposomes in the rat. J Pharm Pharmacol 1992; 44:707.
35. Saba TM. Physiology and physiopathology of the reticuloendothelial system. Arch Intern Med 1970; 126:1031.
36. Harashima H, Sakata K, Kiwada H. Distinction between the depletion of opsonins and the saturation of uptake in the dose-dependent hepatic uptake clearance of liposomes. Pharm Res 1993; 10:606.
37. Boxenbaum H. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokin BioPharm 1982; 10:201.
38. Sawada Y, Hanano M, Sugiyama Y, Harashima H, Iga T. Prediction of the volume of distribution of basic drugs in humans based on data from animals. J Pharmacokin BioPharm 1984; 12:587.
39. Mordenti J, Chen SA, Moore JA, Ferraiolo BL, Green JD. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res 1991; 8:1351.
40. Harashima H, Komatsu S, Kojima S, Yanagi C, Morioka Y, Naito M, Kiwada H. Species difference in the disposition of liposomes among mice, rats and rabbits: allometric relationship and species dependent hepatic uptake mechanism. Pharm Res 1996; 7:1049.
41. Harashima H, Kiwada H. Studies on the hepatic uptake mechanism of liposomes with isolated perfused liver system. J Liposome Res 1996; 6:61.
42. Kirby C, Larke J, Gregoriadis G. Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochem J 1980; 186:591.
43. Kirby C, Gregoriadis G. The effect of the cholesterol content of small unilamellar liposomes on the fate of their lipid components in vivo. Life Sci 1980; 27:2223.
44. Scherphof G, Roerdink F, Waite M, Parks J Disintegration of phosphatidylcholine liposomes in plasma as a result of interaction with high-density lipoproteins. Biochim Biophys Acta 1978; 542:296.
45. Tomlilnson S. Complement defense mechanisms. Curr Opin Immunol 1993; 5:83.
46. Chonn A, Semple SC, Cullis PR. Association of blood proteins with large unilamellar liposomes in vivo: relation to circulation lifetimes. J Biol Chem 1992; 267:18759.
47. Harashima H, Ochi Y, Kiwada H. Kinetic modeling of liposome degradation in serum: effect of size and concentration of liposomes in vitro. BioPharm Drug Disposit 1994; 15:217.
48. Harashima H, Kume Y, Yamane C, Kiwada H. Kinetic modeling of liposome degradation in blood circulation. BioPharm Drug Disposit 1993; 14:265.
49. Harashima H, Hiraiwa T, Ochi Y, Kiwada H. Size dependent liposome degradation in blood: in vivo/in vitro correlation by kinetic modeling. J Drug Target 1995; 3:253.
50. Mayer LD, Tai LCK, Ko DSC, Masin D, Ginsberg RS, Cullis PR, Bally MB. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin im mice. Cancer Res 1989; 49:5922.
51. Boman NL, Mayer LD, Cullis PR. Optimization of the retention properties of vincristine in liposomal systems. Biochim Biophys Acta 1993; 1152:253.
52. Boman NL, Masin D, Mayer LD, Cullis PR, Bally MB. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res 1994; 54:2830.
53. Rahman A, Carmichael D, Harris M, Roh JK. Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. Cancer Res 1986; 46:2295.
54. Urakami Y, Harashima H, Iidda S, Nagayasu A, Kiwada H. Kinetic study on the optimization of tumor delivery of antitumor agents by liposomes: simulation study based on the physiological modeling. Drug Deliv Sys 1997; 12:403.
55. Butler TP, Grantham FH, Gullino PM. Bulk transfer of fluid in the interstitial compartment of mammary tumors. Cancer Res 1975; 35:3084.
56. Jain RK. Determination of tumor blood flow: a review. Cancer Res 1988; 48:2641.
57. Eskey CJ, Wolmark N, McDowell CL, Domach MM, Jain RK. Residence time distributions of various tracers in tumors: implications for drug delivery and blood flow measurement. J Natl Cancer Inst 1994; 86:293.
58. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee KD, Woodle MC, Lasic DD, Redemann C, Martin FJ. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A 1991; 88:11460.
59. Huang SK, Lee KD, Hong K, Friend DS, Papahadjopoulos D. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res 1992; 52:5135.
60. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. Microvascular permeability and interstitial penetration of sterically stabilized (Stealth®) liposomes in a human tumor xenograft. Cancer Res 1994; 54:3352.
61. Harasym TO, Cullis PR, Bally MB. Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes. Cancer Chemother Pharmacol 1997; 40:309.
62. Mayhew E, Cimino M, Klemperer J, Lazo R, Wiernikowski J, Arbuck S. Free and liposomal doxorubicin treatment of intraperitoneal colon 26 tumor: therapeutic and pharmacologic studies. Select Cancer Therap 1990; 6:193.
63. Inaba M, Johnson RK. Uptake and retention of adriamycin and daunorubicin by sensitive and anthracycline-resistant subline of P388 leukemia, Biochem Pharm 1978; 27:2123.
64. Bally MB, Masin D, Nayar R, Cullis P., Mayer LD. Transfer of liposomal drug carriers from the blood to the peritoneal cavity of nomal and ascitic tumor-bearing mice. Cancer Chemother Pharmacol 1994; 34:137.
65. Ozawa S, Sugiyama Y, MItsuhashi Y, Kobayashi T, Inaba M. Cell killing action of cell cycle phase-non-specific antitumor agents is dependent on concentration-time product. Cancer Chemother Pharmacol 1988; 21:185.
66. Evans WE, Relling MV. Clinical pharmacokinetics-pharmacodynamics of antitumor drugs. Clin Pharmacokin 1989; 16:327.
67. Uchiyama K, Nagayasu A, Yamagiwa Y, Nishida T, Harashima H, Kiwada H. Effects of the size and fluidity of liposomes on their accumulation in tumors: a presumption of their interaction with tumors. Int J Pharm 1995; 121:195.
68. Parker RJ, Hartman KD, Sieber SM. Lymphatic absorption and tissue disposition of liposomeentrapped [14C]adriamycin following intraperitoneal administration to rats. Cancer Res 1981; 41:1311.
69. Flessner MF, Dedrick RL, Schultz JS. Exchange of macromolecules between peritoneal cavity and plasma. Am J Physiol 1984; 248:H15.
70. Gabizon A, Shiota R, Papahadjopoulos D. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J Natl Cancer Inst 1989; 81:1484.
71. Yamaoka K, Nakagawa TA. Nonlinear least squares program based on differential equations, MULTI(RUNGE), for microcomputers. J Pharmacobiodyn 1983; 6:595.
72. Huang SK, Mayhew R, Gilani S, Lasic DD, Martin FJ, Papahadjopoulos D. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res 1992; 52:6774.
73. Kirpotin D, Park JW, Hong K, Zalipsky S, Li WL, Carter P, Benz CC, Papahadjopoulos D. Sterically stabilized antiHER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 1997; 36:66.
74. Suzuki V, Inoue K, Hongoh A, Hashimoto Y, Yamazoe Y. Modulation of doxorubicin resistance in a doxorubicin-resistant human leukaemia cell by an immunoliposome targeting transferring receptor. Br J Cancer 1997; 76:83.
75. K. Maruyama, et al. Immunoliposomes bearing polyethlenglycol-coupled Fab′ fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo. FEBS Lett 1997; 413:177.
76. DEL de Menezes, Pilarski LM, Allen TM. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res 1998; 58:3320.
77. Mayer, LD, Tai LCL, Bally MB, Mitilenes GN, Ginsberg RS, Cullis PR. Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. Biochim Biophys Acta 1990; 1025:143.
78. Allen TM, Agrawal AK, Ahmad I, Hansen CB, Zalipsky S. Antibody-mediated targeting of long-circulating (Stealth®) liposomes. J Liposome Res 1994; 4:1.
79. Allen TM, Hansen CB, Zlipsky S. Antibody-targeted Stealth® liposomes. In: Lasic DD, Martin FJ, editors. Stealth Liposomes. Boca Raton, FL: CRC Press, 1995.
80. Allen TM, Brandeis E, Hansen CB, Kao GY, Zalipsky S. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim Biophys Acta 1995; 1237:99.
81. Zalipsky S. Synthesis of end-group functionalized polyethylene glycol-lipid conjugates for preparation of polymer-grafted liposomes. Bioconjugate Chem 1993; 4:296.
82. Kirpotin D, Park JW, Hong K, Zalipsky S, Li WL, Carter P, Benz CC, Papahadjopoulos D. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 1997; 36:66.
83. Ishida T, Iden DL, Allen TM. A combinatorial approach to producing sterically stabilized (Stealth®) immunoliposomal drugs. FEBS Lett 1999; 460:129.
84. Iden D, Allen T. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. Biochim Biophys Acta 2001; 1513:207.
85. Ghetie MA, Picker LJ, Richardson JA, Tucker K, Uhr JW, Vitetta ES. Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest. Blood 1994; 83:1329.
86. Pietras RJ, Fendly BM, Chazin VR, Pergram MD, Howell SB, Slamon DJ. Antibody to HER2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994; 9:1829.
87. Matthay KK, Abai AM, Cobb S, Hong K, Papahadjopoulos D, Straubinger RM. Role of ligand in antibody-directed endocytosis of liposomes by human T-leukemia cells. Cancer Res 1989; 49:4879.
88. Goldmacher VS, Scott CF, Lambert JM, McIntyre GD, Blattler WA, Collinson AR, Cook SA, Slayter HS, Beaumont E, Watkins S. Cytotoxicity of gelonin and its conjugates with antibodies is determined by the extent of their endocytosis. J Cell Phys 1989; 141:222.
89. Berinstein N, Matthay KK, Papahadjopoulos D, Levy R, Sikic BI. Antibody-directed targeting of liposomes to human cell lines: role of binding and internalization on growth inhibition. Cancer Res 1987; 47:5954.
90. Huang A, Kennel SJ, Huang L. Interactions of immunoliposomes with target cells. J Biol Chem 1983; 258:14034.
91. Hansen CB, Kao GY, Moase EH, Zalipsky S, Allen TM. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim Biophys Acta 1995; 1239:133.
92. , Debs RJ, Heath TD, Papahadjopoulos D, Targeting of anti-Thy 1.1 monoclonal antibody conjugated liposomes in Thy 1.1 mice after intravenous administration. Biochim Biophys Acta 1987; 901:183.
93. Aragnol D, Leserman L. Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo. Proc Natl Acad Sci U S A 1986; 83:2699.
94. Maruyama K, Takizawa T, Takahashi N, Tagawa T, Nagaike K, Iwatsuru M. Factors influencing longevity and target binding of PEG-immunoliposomes conjugated antibodies at PEG's terminals. J Liposome Res 1996; 6:206.
95. 1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo. FEBS Lett 1991; 284:263.
96. Zalipsky S, Newman M, Punatambekar B, Woodle MC. Model ligands linked to polymer chains on liposomal surfaces: application of a new functionalized polyethylene glycol-lipid conjugate. Polymer Mater Sci Eng 1993; 67:519.
97. Torchilin VP, Narula J, Halpern E, Khaw BA. Poly(ethylene glycol)-coated anti-cardiac myosin immunoliposomes: factors influencing targeted accumulation in the infarcted myocardium. Biochim Biophys Acta 1996; 1279:75.
98. Torchilin VP, Klibanov AL, Huang L, O'Donnell S, Nossiff ND, Khaw, BA. Targeted accumulation of polyethylene glycol-coated immunoliosomes in infarcted rabbit myocardium. FASEB J 1992; 6:2716.
99. Lopes de Menezes DE, Pilarski LM, Allen TM. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res 1998; 58:3320.
100. Park JW, Hong K, Carter P, Asgari H, Guo LY, Keller GA, Wirth C, Shalaby R, Kotts C, Wood WI, Papahadjopoulos D, Benz CC. Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci U S A 1995; 92:1327.
101. Park JW, Hong K, Kirpotin DB, Meyer O. Anti-HER2 immunoliposomes for targeted therapy of human tumors. Cancer Lett 1997; 118:153.
102. Park JW, Kirportin DB, Hong K, Shalaby R, Shao Y, Nielson UB, Marks JD, Papahadjopoulos D, Benz CC. Tumor targeting using anti-her2 immunoliposomes. J Control Release 2001; 74:95.
103. Di Fiorre PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA. A human growth-receptor like gene (erb-B2) is a potent oncogene when overexpressed NIH/3T3 cells. Science 1987; 237:178.
104. Di Fiorre PP, Segatto O, Aaronson SA. Cloning, expression and biological effects of the erbB2/neu gene in mammalian cells. Methods Enzymol 1991; 198:272.
105. Park JW, Hong K, Kirpotin DB, Papahadjopoulos D, Benz CC. Immunoliposomes for cancer treatment. Adv Pharmacol 1997; 40:399.
106. Allen TM, Ahmad I, Lopes de Menezes DE, Moase EH. Immunoliposome-mediated targeting of anti-cancer drugs in vivo. Biochem Soc Trans 1995; 3:1073.
107. Gates SB, Mendelsohn LG, Shackelford KA, Habeck LL, Kursar JD, Gossett LS, Worzalla JF, Shin C, Grindey GB. Characterization of folate receptor from normal and neoplastic murine tissue: influence of dietary folate on folate receptor expression. Clin Cancer Res 1996; 2:1135.
108. Weitman SD, Lark RH, Coney LR, Fort DW, Frasca V, Zurawski VRJ, Kamne BA. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 1992; 52:3396.
109. Kranz DM, Patrick TA, Brigle KE, Sprinella MJ, Roy EJ. Conjugates of folates and anti-T-cell receptor antibodies specifically target folate-receptor-positive tumor cells for lysis. Proc Natl Acad Sci U S A 1995; 92:9057.
110. Wang S, Low PS. Folate mediated targeting of anti-neoplastic drugs, imaging agents, and nucleic acids to cancer cells. J Control Release 1998; 53:39.
111. Reddy JA, Low PS. Folate-mediated targeting of therapeutic and imaging agents to cancer. Crit Rev Ther Drug Carrier Sys 1998; 15:587.
112. Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev 2000; 41:147.
113. Lee RJ, Low PS. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem. 1994; 269:3198.
114. Lee RJ, Low PS. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta 1995; 1233:134.
115. Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S, Gabizon A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res 2000; 6:1949.
116. Kohgo Y, Nittsu Y, Nishisato T, Kato J. Externalization of transferrin receptor in established human cell lines. Cell Biol Int Rep 1987; 11:871.
117. Rossi MC, Zetter BR. Selective stimulation of prostatic carcinoma cell proliferation by transferrin. Proc Natl Acad Sci U S A 1992; 89:6197.
118. Inoue T, Cavanaugh PG, Steck PA, Brummer N, Nicolson GL. Differences in transferrin response and numbers of transferrin receptors in rat and human mammary carcinoma lines of different metastatic potentials. J Cell Physiol 1993; 156:212.
119. Sarti P, Ginobbi P, D'Agostino I, Arancia G, Lendaro E, Molinari A, Ippoliti R, Citro G. Liposomal targeting of leukemia HL60 cells induced by transferrin-receptor endocytosis. Biotechnol Appl Biochem 1996; 24:269.
120. Eavarone DA, Yu X, Ballamkonda RV. Targeted drug delivery to C6 glioma by transferrincoupled liposomes. J Biomed Mater Res 2000; 51:10.
121. Maruyama K, Ishida O, Takizawa T, Moribe K. Possibility of active targeting to tumor tissues with liposomes. Adv Drug Deliv Rev 1999; 40:89.
122. Ishida O, Maruyama K, Tanahashi H, Iwatsuru M, Sasaki K, Eriguchi M, Yanagie H. Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharm Res 2001; 18:1042.
123. Park JW, Kirpotin D, Hong R, Shalaby R, Shao Y, Nielsen U, Marks J, Papahadjopoulos D. Anti-HER2 immunoliposomes: enhanced efficacy via intracellular delivery. Proc Am Assoc Cancer Res 2000; 41:524.
124. Hong K, Kirpotin DB, Park JW, Shao Y, Shalaby R, Colbern G, Benz CC. Papahadjopoulos D. Anti-HER2 immunoliposomes for targeted drug delivery. Am N Y Acad Sci U S A 1999; 886:293.
125. Lopes de Menezes DE, Pilarski LM, Allen TM. Selective cytoxicity of immunoliposomal to B lymphocytes. Proc Am Assoc Cancer Res 1995; 36:307.
126. Tseng Y, Hong R, Tao M, Chang F. Sterically stabilized anti-idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma model. Int J Cancer 1999; 80:723.
127. Moase EH, Qi W, Ishida T, Gabos Z, Longenecker BM, Zimmermann GL, Ding L, Krantz M, Allen TM. Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer. Biochim Biophys Acta 2001; 1510:43.
128. Allen TM. Oncologic agents in sterically stabilized liposomes: basic considerations. In: Woodle MC, editor. Long-Circulating Liposomes: Old Drugs, New Therapy. Georgetown, TX: Landes Bioscience, 1998.
129. Baldini N, Scotlandi K, Serra M, Shikita T, Zini N, Ognibene A, Senti S, Ferracini R, Maraldi NM. Nuclear immunolocalization of P-glycoprotein in multidrug-resistance cell lines showing similar mechanisms of doxorubicin distribution. Eur J Cell Biol 1995; 68:226.
130. Germann UA. P-glycoprotein - a mediator of multidrug resistance in tumor cells. Eur J Cancer 1996; 32:927.
131. Yatvin MB, Kreutz W, Horwitz BA, Shinitzky M. pH-sensitive liposomes: possible clinical implications. Science 1980; 210:1253.
132. Nayar R, Schroit AJ. Generation of pH-sensitive liposomes: use of large unilamellar vesicles containing N-succinyldioleoylphosphatidylethanolamine. Biochemistry 1985; 24:5967.
133. Connor J, Yatvin MB, Huang L. pH-sensitive liposomes: acid-induced liposome fusion. Proc Natl Acad Sci U S A 1984; 81:1715.
134. Duzgunes N, Straubinger RM, Baldwin PA, Friend DS, Papahadjopoulos D. Proton-induced fusion of oleic acid-phosphatidylethanolamine liposomes. Biochemistry 1985; 24:3091.
135. Connor J, Huang L. Efficient cytoplasmic delivery of a fluorescent dye by pH-sensitive immunoliposomes. J Cell Biol 1985; 101:582.
136. Straubinger RM, Duzgunes N, Papahadjopoulos D. pH-sensitive liposomes mediate cytoplasmic delivery of encapsulated macromolecules. FEBS Lett 1985; 179:148.
137. Ellens H, Bentz J, Szoka FC. Destabilization of phosphatidylethanolamine liposomes at the hexagonal phase transition temperature. Biochemistry 1986; 25:285.
138. Ellens H, Bentz J, Szoka FC. Fusion of phosphatidylethanolamine-containing liposomes and mechanism of the La-HII phase transition, Biochemistry 1986; 25:4141.
139. Tachibana R, Harashima H, Shono M, Azumano M, Niwa M, Futaki S, Kiwada H, Intracellular regulation of macromolecules using pH-sensitive liposomes and nuclear localization signal: qualitative and quantitative evaluation of intracellular trafficking. Biochem Biophys Res Comm 1998; 251:538.
140. Litzinger DC, Huang L. Phosphatidylethanolamine liposomes: drug delivery, gene transfer and immunodiagnostic applications. Biochim Biophys Acta 1992; 1113:201.
141. Boycott R, Klenk HD, Ohuchi M. CeUtropism of influenza virus mediated by hemagglutinin activation at the stage of virus entry. Virology 1994; 203:313.
142. Bullough PA, Hughson FM, Skehel JJ, Wiley DC. Structure of influenza haemagglutimin at the pH of membrane fusion. Nature 1994; 371:37.
143. Plank C, Oberhauser B, Mechtler K, Koch C, Wagner E. The influence of endosome-disruptive peptides on gene transfer using synthetic virus-like gene transfer system. J Biol Chem 1994; 269:12918.
144. Nishikawa M, Yamauchi M, Morimoto K, Ishida E, Takakura Y, Hashida M. Hepatocytetargeted in vivo gene expression by intravenous injection of plasmid DNA complexed with synthetic multi-functional gene delivery system. Gene Ther 2000; 7:548.
145. Subbarao NK, Parente RA, Szoka FC Jr., Nadasdi L, Pongracz K. pH-dependent bilayer destabilization by an amphipathic peptide. Biochemistry 1987; 26:2964.
146. Goormaghtigh E, De Meutter J, Szoka F, Cabiaux V, Parente RA, Ruysschaert JM, Secondary structure and orientation of the amphipathic peptide GALA in lipid structures. An infraredspectroscopic approach. Eur. J Biochem. 1991; 195:421.
147. Parente RA, Nir S, Szoka FC Jr. pH-dependent fusion of phosphatidylcholine small vesicles. Induction by a synthetic amphipathic peptide. J Biol Chem 1988; 263:4724.
148. Parente RA, Nir S, Szoka FC Jr. Mechanism of leakage of phospholipid vesicle contents induced by the peptide GALA. Biochemistry 1990; 29:8720.
149. Nicol F, Nir S, Szoka FC Jr. Orientation of the pore-forming peptide GALA in POPC vesicles determined by a BODIPY-avidin/biotin binding assay. Biophys J 1999; 76:2121.
150. Nieva JL, Nir S, Muga A, Goni FM, Wilschut J Interaction of the HIV-1 fusion peptide with phospholipid vesicles: different structural requirements for fusion and leakage. Biochemistry 1994; 33:3201.
151. Simoes S, Slepushkin V, Gaspar R, de Lima MC, Duzgunes N. Gene delivery by negatively charged ternary complexes of DNA, cationic liposomes and transferrin or fusigenic peptides. Gene Ther 1998; 5:955.
152. Nakielny S, Dreyfuss G. Transport of proteins and RNAs in and out of the nucleus. Cell 1999; 99:677.
153. Stoffier D, Fahrenkrog B, Aebi U. The nuclear pore complex: from molecular architecture to functional dynamics. Curr Opin Cell Biol 1999; 11:391.
154. Allen TD, Cronshaw JM, Bagley S, Kiseleva E, Goldberg MW. The nuclear pore complex: mediator of translocation between nucleus and cytoplasm. J Cell Sci 2000; 113:1651.
155. Wente SR. Gatekeepers of the nucleus. Science 2000; 288:1374.
156. Yoneda Y. Nucleocytoplasmic protein traffic and its significance to cell function. Genes Cells 2000; 5:777.
157. Stewart M, Baker RP, Bayliss R, Clayton L, Grant RP, Littlewood T, Matsuura Y. Molecular mechanism of translocation through nuclear pore complexes during nuclear protein import. FEBS Lett 2001; 498:145.
158. Sebestyén MG, Ludtke JJ, Bassik MC, Zhang G, Budker V, Lukhtanov EA, Hagstrom JE, Wolff JA. DNA vector chemistry: the covalent attachment of signal peptides to plasmid DNA. Nat Biotechnol 1998; 16:80.
159. Zanta MA, Belguise Valladier P, Behr JP. Gene delivery: a single nuclear localization signal peptide is sufficient to carry DNA to the cell nucleus. Proc Natl Acad Sci U S A 1999; 96:91.
160. Brandén LJ, Mohamed AJ, Smith CI. A peptide nucleic acid-nuclear localization signal fusion that mediates nuclear transport of DNA. Nat Biotechnol 1999; 17:784.
161. Zelphati O, Liang X, Nguyen C, Barlow S, Sheng S, Shao Z, Felgner PL. PNA-dependent gene chemistry: stable coupling of peptides and oligonucleotides to plasmid DNA. Biotechniques 2000; 28:304.
162. Goren D, Horowitz AT, Zalipsky S, Woodle MC, Yarden Y, Gabizon A. Targeting of stealth liposomes to erB-2 (Her/2) receptor: in vitro and in vivo studies. Br J Cancer 1996; 74:1749.
163. Ishii Y, Aramaki Y, Hara T, Tsuchiya S, Fuwa T. Preparation of EGF labeled liposomes and their uptake by hepatocytes. Biochem Biophys Res Commun 1989; 160:732.
164. Kikuchi A, Sugaya S, Ueda H, Tanaka K, Aramaki Y, Hara T, Arima H, Tsuchiya S, Fuwa T. Efficient gene transfer to EGF receptor overexpressing cancer cells by means of EGF-labeled cationic liposomes. Biochem Biophys Res Commun 1996; 227:666.
165. Lundberg B, Hong K, Papahadjopoulos D. Conjugation of apolipoprotein B with liposomes and targeting to cells in culture. Biochim Biophys Acta 1993; 1149:305.
166. Vidal M, Sainte Marie J, Philippot JR, Bienvenue A. LDL-mediated targeting of liposomes to leukemic lymphocytes in vitro. EMBO J 1985; 4:2461.
167. Eliaz RE, Szoka FCJ. Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer Res 2001; 15:2592.
168. Pagnan G, Montaldo PG, Pastorino F, Chiesa L, Raffaghello L, Kirchmeier M, Allen TM, Ponzoni M. GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinide. Int J Cancer 1999; 81:268.
169. Pagnan G, Stuart DD, Pastorino F, Raffaghello L, Montaldo P, Allen TM, Calabretta B, Ponzoni M. Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD2-targeted immunoliposomes: antitumor effects. J Natl Cancer Inst 2000; 92:253.
170. Regimbald LH, Pilarski LM, Longenecker BM, Reddish MA, Zimmermann G, Hugh JC. The breast mucin MUC1 as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res 1996; 56:4244.
171. Sugano M, Egilmez NK, Yokota SJ, Chen F, Harding J, Huang SK, Bankert RB. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Cancer Res 2000; 60:6942.
172. Suzuki S, Inoue K, Hongoh A, Hashmoto Y, Yamazoe Y. Modulation of doxorubicin resistance in a doxorubicin-resistant human leukaemia cell by an immunoliposome targeting transferrin receptor. Br J Cancer 1997; 76:83.
173. Allen TM, Lopes de Menezes D, Hansen CB, Moase EH. Strategies for Stealth® Therapeutic Systems. In: Gregoriadis G, McCormack B, editors. Targeting of Drugs. New York: Plenum, 1998.